1. Why This Article Matters — Why You Should Read This
Corticosteroids are everywhere in critical care. ARDS. Septic shock. COVID-19. Refractory hypoxemia.
But when it comes to hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), their role remains controversial, inconsistently applied, and poorly understood.
This narrative review tackles a clinically uncomfortable reality:
While steroids may blunt inflammation, they can simultaneously impair host defense, delay pathogen clearance, and increase secondary infections.
Given that HAP and VAP remain among the leading causes of ICU mortality, understanding when steroids help — and when they harm — is essential.
This article synthesizes mechanistic data, randomized trials, and observational studies to clarify what the evidence actually supports in 2025.
2. The Article in 5 Lines
- HAP occurs ≥48 hours after hospital admission; VAP occurs ≥48–72 hours after initiation of mechanical ventilation.
- Mortality remains high, ranging from 20–35%, and approaching 50% in high-risk VAP populations.
- Corticosteroids theoretically reduce lung inflammation but may worsen infection control.
- Evidence does not support routine steroid use in HAP or VAP.
- Any potential benefit appears context-dependent, influenced by pathogen type, dose, timing, and host factors.
3. What They Actually Found — The Clinically Important Insights
1️⃣ HAP and VAP remain distinct but overlapping syndromes
- HAP: pneumonia developing ≥48 hours after admission, without mechanical ventilation
- VAP: pneumonia developing ≥48–72 hours after intubation
Despite shared pathogens, VAP is associated with:
- higher bacterial burden
- greater inflammatory response
- longer ICU stays
- higher mortality
These distinctions matter when extrapolating steroid data.
2️⃣ The biological rationale for steroids is compelling — but incomplete
Steroids can:
- suppress excessive pulmonary inflammation
- reduce capillary leak
- improve oxygenation
- decrease systemic cytokine release
However, they also:
- impair neutrophil and macrophage function
- reduce pathogen clearance
- mask fever and inflammatory markers
- increase risk of secondary and opportunistic infections
This duality explains the mixed clinical results.
3️⃣ Evidence in bacterial HAP/VAP is inconsistent and weak
Randomized trials and meta-analyses show:
- no consistent mortality benefit Low-dose steroids may shorten:
- duration of mechanical ventilation
- ICU length of stay
But these benefits are modest and not reproducible across studies.
4️⃣ Viral pneumonias tell a different — and more concerning — story
In influenza-associated pneumonia and viral ARDS:
- Steroids are associated with
COVID-19 is an exception only when hypoxemia and systemic inflammation are present, not as a treatment for pneumonia itself.
5️⃣ Dose and duration are critical determinants of harm
- Low-dose, short-course regimens (≤400 mg hydrocortisone equivalent/day, 5–14 days) → lower complication rates
- Higher doses (e.g., dexamethasone ≥12 mg/day) → increased infections, hyperglycemia, myopathy, and mortality
This dose-response relationship is consistent across studies.
6️⃣ Timing matters more than many clinicians realize
Late steroid initiation:
- may suppress adaptive immunity
- may worsen bacterial persistence
- may confound clinical assessment of treatment response
Early use without clear inflammatory indications risks overtreatment.
7️⃣ Steroids complicate diagnosis and monitoring
Corticosteroids:
- blunt fever
- suppress CRP and procalcitonin
- obscure clinical deterioration
This may delay recognition of:
- treatment failure
- new infections
- complications such as empyema or abscess
A major practical downside highlighted by the authors.
8️⃣ Current guidelines do NOT recommend routine steroid use
Major societies agree:
- No role for routine corticosteroids in HAP or VAP
- Possible consideration only in:
Even then, decisions must be individualized.
9️⃣ Precision medicine, not protocol medicine, is the future
The authors emphasize that:
- pneumonia is not a uniform inflammatory disease
- host response varies widely
- blanket steroid strategies are inappropriate
Future trials must:
- phenotype patients
- stratify by pathogen
- incorporate immune profiling
🔟 The evidence gap remains substantial
Key unanswered questions include:
- Which biomarkers identify steroid responders?
- Can immune phenotyping guide therapy?
- How do steroids interact with modern antimicrobial strategies?
Until then, caution is warranted.
4. How This Should Influence Your Practice
- Do not use steroids routinely for HAP or VAP.
- Assess pathogen type carefully — viral vs bacterial matters.
- Limit dose and duration if steroids are used for overlapping indications.
- Monitor closely for secondary infections and masked deterioration.
- Individualize decisions — avoid reflexive steroid escalation.
5. Bottom Line for Clinicians
Corticosteroids are not standard therapy for HAP or VAP — and indiscriminate use may do more harm than good.
Their role, if any, is narrow, context-dependent, and requires careful patient selection.
This review reinforces a critical principle of modern critical care:
Inflammation should be treated precisely — not blindly.
6. Discussion Question
In patients with severe HAP or VAP, what factors should guide steroid use in your ICU — pathogen, inflammatory phenotype, ARDS overlap, or severity alone?
We look forward to the discussion.
